why choose us

First received: May 23, 2023

Clinical Trial: Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pancreatic Ductal Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase II Open-Label Study of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)

Brief Summary: A Phase II Open-Label Study of Enfortumab Vedotin in Patients with Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)

Read more